Targeting KAT7 inhibits the progression of colorectal cancer
Theranostics · 02.01.2025 · 15 (4) · 1478-1495
DOI: 10.7150/thno.106085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 02.01.2025. Verfasst von Hao Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Histone Acetyltransferases. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
Colorectal cancer (CRC) is a leading cause of cancer-related mortality. Epigenetic modifications play a significant role in the progression of CRC. KAT7, a histone acetyltransferase, has an unclear role in CRC.
Methods
In this research, we analyzed the expression of KAT7 in CRC patients and its correlation with prognosis using the GEO database, western blot, and immunohistochemistry. We assessed the impact of KAT7 on CRC cell functions through cell viability, colony formation, flow cytometry, scratch, and transwell assays. Mechanistic insights were obtained via RNA sequencing and ChIP-qPCR. Additionally, we evaluated the effects of KAT7 on CRC growth and metastasis in vivo using mouse subcutaneous tumor and lung metastasis models.
Results
In this study, we discovered an upregulated KAT7 signaling pathway in CRC and its association with poor patient survival. Knockdown of KAT7 promotes apoptosis and inhibits proliferation, migration, and invasion of CRC cells. Conversely, KAT7 overexpression enhanced these cellular processes. In vivo assays confirmed that knockdown of KAT7 can inhibit CRC proliferation and lung metastasis. Mechanistically, KAT7 acetylated histone H3 at lysine 14 (H3K14) to enhance MRAS transcription, which activated the MAPK/ERK pathway and promoted tumorigenesis. The enzymatic function of KAT7 as an acetyltransferase is crucial for the advancement of colorectal cancer. In KAT7 knockdown CRC cells, re-expression of KAT7, but not an acetyltransferase-deficient mutant, rescued MRAS expression, ERK phosphorylation, and CRC tumorigenesis.
Conclusion
We found that KAT7 is highly expressed in CRC patients, and those with high KAT7 expression have a worse prognosis. KAT7 enhances MRAS gene transcription by promoting H3K14 acetylation, thereby activating the MAPK/ERK pathway and promoting malignant phenotypes of CRC. In summary, KAT7 represents a promising target for CRC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
- Guangdong Engineering Research Center of Precision Immune Cell Therapy Technology, Guangzhou, 510280, China.
- Cancer Center, The 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Guangdong, 523059, China.
- Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
- Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan Engineering Research Center for Innovative Boron Drugs and Novel Radioimmune Drugs, The T…
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510280, China.
Zitieren
APA
Wang, H., Guan, T., Hu, R., Huang, Z., Liang, Z., Lin, X., Qiu, Y., Liao, P., Guo, X., Ke, Y., Zhang, H., Ou, C., & Li, Y. (2025). Targeting KAT7 inhibits the progression of colorectal cancer. Theranostics, 15(4), 1478-1495. https://doi.org/10.7150/thno.106085
Vancouver
Wang H, Guan T, Hu R, Huang Z, Liang Z, Lin X, et al. Targeting KAT7 inhibits the progression of colorectal cancer. Theranostics. 2025;15(4):1478-1495. doi:10.7150/thno.106085
BibTeX
@article{Wang2025,
author = {Wang, Hao and Guan, Tianwang and Hu, Rong and Huang, Zhongjie and Liang, Zhao and Lin, Xiaonan and Qiu, Yingqi and Liao, Peiyun and Guo, Xiongbo and Ke, Yushen and Zhang, Honghao and Ou, Caiwen and Li, Yuhua},
title = {Targeting KAT7 inhibits the progression of colorectal cancer},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {4},
pages = {1478--1495},
doi = {10.7150/thno.106085}
}
EUVIMED